A 42-year-old woman from Bangalore presents with progressive abdominal distension and pelvic heaviness for 18 months. She denies vaginal bleeding. On examination, the uterus is firm, massively enlarged (approximately 20-week size), and irregular. Pelvic ultrasound confirms multiple intramural and subserosal fibroids, the largest measuring 8 cm. She has not completed childbearing and desires fertility preservation. Hemoglobin is 11.8 g/dL. What is the most appropriate initial management?

Explanation

## Clinical Context This patient has **multiple large fibroids** causing mass effect (abdominal distension, pelvic heaviness) but **not menorrhagia**. Critically, she **has not completed childbearing** and desires fertility preservation. The uterus is massively enlarged (20-week size). ## Why GnRH Agonist Is Correct **Key Point:** In women with **large, multiple fibroids who desire fertility preservation**, GnRH agonist is the appropriate **initial** step to: 1. Reduce fibroid size (typically 40–60% shrinkage over 3–6 months) 2. Reduce uterine volume and mass effect symptoms 3. Improve surgical feasibility if myomectomy is later needed 4. Optimize hemoglobin before surgery 5. **Allow time for counseling** on the high recurrence rate (15–30%) and impact on future fertility **Clinical Pearl:** GnRH agonists induce a **hypogonadal state** that shrinks fibroids temporarily. In women with **large uteri (>12–14 weeks size)** or **multiple fibroids**, preoperative GnRH agonist reduces operative blood loss, operative time, and conversion to hysterectomy. **High-Yield:** GnRH agonist is **NOT definitive therapy** but a **preoperative adjunct** in: - Large fibroids (>4 cm) - Multiple fibroids - Massive uterine enlargement - Desire for fertility preservation - Need to optimize hemoglobin ## Management Algorithm for Fibroids in Reproductive-Age Women ```mermaid flowchart TD A[Symptomatic Fibroid]:::outcome --> B{Completed Childbearing?}:::decision B -->|Yes| C[Myomectomy or Hysterectomy]:::action B -->|No| D{Fibroid Size & Number?}:::decision D -->|Small, Single| E[Myomectomy]:::action D -->|Large/Multiple| F[GnRH Agonist 3-6 months]:::action F --> G[Reassess & Counsel on Recurrence]:::action G --> H{Proceed with Myomectomy?}:::decision H -->|Yes| I[Myomectomy]:::action H -->|No| J[Observation or Repeat GnRH]:::action ``` ## GnRH Agonist: Mechanism & Timing | Feature | Detail | |---------|--------| | **Mechanism** | Downregulation of GnRH receptors → ↓ FSH/LH → hypogonadism → fibroid shrinkage | | **Fibroid shrinkage** | 40–60% reduction in volume over 3–6 months | | **Duration of effect** | Temporary; fibroids regrow after discontinuation | | **Indications** | Large fibroids, multiple fibroids, massive uterus, preop optimization | | **Contraindications** | Desire for immediate pregnancy (induces hypogonadal state) | | **Side effects** | Hot flushes, vaginal dryness, bone loss (if >6 months) | **Mnemonic:** **GnRH = "Give Now, Reassess, Help fertility"** — use GnRH agonist preoperatively in large/multiple fibroids to shrink them, then reassess and help preserve fertility with myomectomy. [cite:Telinde's Operative Gynecology 12e Ch 16; ACOG Practice Bulletin 228]